Healthcare and pharma stocks navigate regulatory shifts, patent cliffs and R&D pipelines; investors weigh earnings resilience against pricing pressures as demographic trends and biotech breakthroughs reshape sector valuations.
The Sei Foundation is contemplating the acquisition of genetic testing company 23andMe, aiming to integrate genetic data onto the blockchain. This move could revolutionize data privacy and accessibility in genetic research, fostering secure and decentralized health solutions.
Jack Wyszomierski, a director at Exelixis, has sold $331,430 worth of company stock, according to recent regulatory filings. This move comes amid fluctuations in Exelixis’ stock price, sparking interest among investors and analysts alike.